Nkarta, Inc. (NKTX)
| Market Cap | 135.66M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -109.24M |
| Shares Out | 71.02M |
| EPS (ttm) | -1.48 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 601,945 |
| Open | 1.950 |
| Previous Close | 1.950 |
| Day's Range | 1.910 - 1.995 |
| 52-Week Range | 1.310 - 5.829 |
| Beta | 0.77 |
| Analysts | Strong Buy |
| Price Target | 13.50 (+606.81%) |
| Earnings Date | Nov 6, 2025 |
About NKTX
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company’s lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravi... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for NKTX stock is "Strong Buy." The 12-month stock price target is $13.5, which is an increase of 606.81% from the latest price.
News
Nkarta to Participate in a September Investor Conference
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today ...
Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights
SOUTH SAN FRANCISCO, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today r...
Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series
SOUTH SAN FRANCISCO, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today a...
Nkarta: Holding Its Support Steady Ahead Of First Data Readouts In 2025
Nkarta shares have remained flat since my last review in March, reflecting a wait-and-see market stance. Pipeline updates show steady progress, but no major catalysts have emerged; data readouts are e...
Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus
SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat...
Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space
Nkarta Inc. NKTX on Wednesday reported a first-quarter loss of 43 cents per share, beating the consensus loss of 44 cents.
Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights
Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus remain open to enrollment Ntrust-1 expanded ...
Nkarta to Participate in an April Investor Conference
SOUTH SAN FRANCISCO, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its p...
Nkarta: Grinding Lower, Trying To Find Support
Nkarta, Inc. has provided significant pipeline updates, showcasing promising advancements in their innovative cell therapy treatments. A financial overview highlights a robust balance sheet, with suff...
Nkarta: Betting On The Turnaround
Nkarta's NKX019 shows promise in treating autoimmune diseases, despite a 70% stock drop; strategic restructuring extends financial runway to 2029. Q4 and full-year 2024 earnings reveal significant R&D...
Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday?
Nkarta, Inc. NKTX reported a fourth-quarter earnings report on Wednesday with a loss of 35 cents per share, beating the consensus of a loss of 41 cents.
Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights
Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseases Initial data for NKX019 in multiple autoim...
Nkarta to Participate in March Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its pa...
Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2
Ntrust-2 open to enroll patients with systemic sclerosis, myositis and ANCA-associated vasculitis across three parallel cohorts
Nkarta to Participate in an Upcoming Investor Conference
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its pa...
Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today r...
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Nkarta to Participate in Upcoming Investor Conference
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its p...
Nkarta: NK Cell Therapy Biotech With Good Standing Targeting R/R NHL Patients
Nkarta, Inc. data from the phase 1 study, using NKX019 for the treatment of patients with relapsed/refractory large B-cell lymphoma, expected by end of 2024. The global non-Hodgkin's Lymphoma Therapeu...
Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
This press release was updated to reflect the correct dosing schedule of the NKX019 investigator-sponsored clinical trial. As previously disclosed, patients enrolled in this trial will receive three d...
Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
SOUTH SAN FRANCISCO, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today r...
Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus
SOUTH SAN FRANCISCO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that r...
Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President
SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced change...
Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications
Patient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engineered NK cell therapy for the treatment of lupus nephritis
Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors
Senior R&D leader brings extensive expertise in immunology, clinical development and translational science Senior R&D leader brings extensive expertise in immunology, clinical development and translat...